Kristina Burow has served as a member of our board of
directors since August 2014. Ms. Burow has served as
Managing Director of ARCH Venture Partners, or ARCH,
since November 2011 and previously held roles of
increasing responsibility at ARCH from August 2002 to
November 2011. Ms. Burow currently serves on the board
of directors of several biopharmaceutical companies,
including Vividion Therapeutics, Inc., Lycera Corp.,
Sienna Biopharmaceuticals, Inc., Metacrine, Inc., UNITY
Biotechnology, Inc., BEAM Therapeutics., AgBiome Inc.,
and AgTech Accelerator. She previously was a co-founder
and member of the board of directors of Receptos, Inc.,
(acquired by Celgene Corporation). Ms. Burow has
participated in a number of other ARCH portfolio
companies including Siluria Technologies, Inc., KYTHERA
Biopharmaceuticals, Inc. (acquired by Allergan), and
Ikaria, Inc. (acquired by Mallinckrodt). Prior to
joining ARCH, Ms. Burow was an Associate with the
Novartis BioVenture Fund in San Diego and an early
employee at the Genomics Institute of the Novartis
Research Foundation. Ms. Burow received a BS in
Chemistry from the University of California, Berkeley,
an MA in Chemistry from Columbia University, and an MBA
from the University of Chicago.
Kristina Burow
Managing Director, ARCH Venture Partners